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Background & Aims: Growth hormone (GH) is used as
therapy for inflammatory bowel disease (IBD), but the
specific effects on intestine are unknown. Transgenic
mice overexpressing GH (MT1-bGH-TG) were used to test
whether increased plasma GH levels alter inflammation
or crypt damage during dextran sodium sulfate (DSS)-
induced colitis. Methods: MT1-bGH-TG and wild-type
(WT) littermates were given 3% DSS for 5 days followed
by up to 10 days of recovery. Colitis and epithelial cell
proliferation were evaluated histologically. Plasma insu-
lin-like growth factor (IGF)-I and colonic IGF-I, interleukin
(IL)-1b, and intestinal trefoil factor (ITF) messenger
RNAs (mRNAs) were measured. Results: DSS induced
similar disease onset in MT1-bGH-TG and WT. More
MT1-bGH-TG survived than WT. By recovery day 7, MT1-
bGH-TG had less inflammation and crypt damage, ele-
vated plasma IGF-I, and increased colonic ITF expression
relative to WT. Colonic IL-1b was elevated in DSS-
treated MT1-bGH-TG and WT, but IL-1b mRNA abun-
dance correlated with disease only in WT. MT1-bGH-TG
showed earlier increases in epithelial cell proliferation
than WT during recovery but only WT showed atypical
repair. Conclusions: GH does not alter susceptibility to
acute DSS-induced colitis but enhances survival, remis-
sion of inflammation, and mucosal repair during recov-
ery. GH therapy may be beneficial during active IBD by
improving mucosal repair.
Ulcerative colitis and Crohn’s disease (CD) arechronic inflammatory diseases of the gastrointesti-
nal tract.1,2 Malabsorption and weight loss are significant
clinical problems in inflammatory bowel disease
(IBD).3–5 Linear growth delay occurs in children with
IBD4,5 and is associated with reduced levels of circulat-
ing insulin-like growth factor (IGF)-I.5 Bowel resection
is a frequent complication of IBD that can further com-
promise nutritional status.6 In CD, extensive resection of
the small bowel leads to short bowel syndrome (SBS) in
a small but clinically significant number of patients.6
There is increasing clinical interest in the use of
trophic factors as therapy in patients with IBD or SBS
because they may improve nutritional status, promote
mucosal repair, and reduce the requirement for paren-
teral nutrition.7–12 In animal models, a number of
growth factors seem to exert protective effects during
intestinal inflammation, including intestinal trefoil fac-
tors13 and transforming growth factor (TGF)-b.14 At
present, recombinant human growth hormone (rhGH) is
one of the few trophic factors in clinical use in patients
with chronic IBD. Several clinical trials indicate benefits
of rhGH therapy in adults with SBS7–11 including 2
placebo-controlled trials in patients with SBS caused by
CD.10,11 Although each study reported that rhGH im-
proved weight gain and lean body mass, there was no
consensus about whether rhGH improved nutrient ab-
sorption.7–11 The 2 studies in CD patients were per-
formed in patients with disease remission and therefore
did not provide information about the effects of rhGH
during ongoing intestinal inflammation and mucosal
damage. A recent study reported decreased Crohn’s Dis-
ease Activity Index, indicative of improvement in symp-
toms, in patients with active CD treated with rhGH.12
Although this indicates benefits of rhGH in patients
with active CD, the specific actions of growth hormone
(GH) on the inflamed colon have not been elucidated. It
seems likely that there will be additional therapeutic
trials of rhGH in patients with IBD, so experimental
evidence about the actions of GH on intestine during
inflammation is desirable.
Abbreviations used in this paper: BrdU, 5*-bromodeoxyuridine; DSS,
dextran sodium sulfate; EGF, epidermal growth factor; IGF, insulin-like
growth factor; ITF, intestinal trefoil factor; rhGH, recombinant human
growth factor; SBS, short bowel syndrome; TGF, transforming growth
factor; WT, wild-type.
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Most, if not all, prior studies of GH action on the
bowel in animal models have focused on the small intes-
tine. GH increased mass of small intestinal mucosa in
hypophysectomized rats,15 in transgenic mice that have
chronic GH excess caused by overexpression of bovine
GH (MT1-bGH-TG),16 and in some17–19 but not all20
studies of animals with proximal small bowel resection.
Little is known about the trophic effects of GH on the
normal or inflamed colon, which is of particular relevance
to the therapeutic effects of rhGH in IBD patients.
One theory of the pathogenesis of IBD is a defect in
colonic healing, resulting in chronic intestinal inflam-
mation. Oral administration of dextran sodium sulfate
(DSS) induces acute colitis, followed by a relatively slow
mucosal repair.21–23 This feature makes the DSS model
useful for studying mechanisms of colonic wound healing
and effects of therapeutic interventions on the healing
process. Information about the recovery phase after DSS
administration may be particularly relevant to develop-
ment of therapies that could accelerate and promote
mucosal repair in patients with active IBD. In the
present study, we used MT1-bGH-TG and wild-type
(WT) littermates to assess whether GH excess alters the
development of and recovery from acute experimental
colitis induced by DSS. Colon was examined for effects of
GH on the severity or extent of inflammation as well as
the amount of crypt damage. Colonic expression of the
proinflammatory cytokine interleukin (IL)-1b was as-
sessed because IL-1b expression is up-regulated during
acute DSS-induced colitis and seems to be involved in
disease severity.24–26
GH increases systemic IGF-I and also increases local
IGF-I expression in the small intestine in some but not
all situations.27,28 Effects of GH on colonic IGF-I expres-
sion have not been reported previously. Benefits of GH
therapy in IBD or experimental models of colitis may be
mediated wholly or in part by circulating or locally
expressed IGF-I. We therefore examined plasma levels of
IGF-I and colonic expression of IGF-I in DSS-treated
MT1-bGH-TG and WT mice and water controls to
determine if any effects of GH excess were associated
with differences in circulating or locally expressed IGF-I.
We also examined the expression of intestinal trefoil
factor (ITF) and TGF-b to determine whether any effects
of GH were associated with altered expression of 2
known mediators of mucosal repair.
Trophic factors such as GH could promote mucosal
healing by promoting proliferation of colonic epithelial
cells, yet few studies have directly assessed crypt cell
proliferation after inflammation-induced damage. IGF-I
is a well-known proliferative factor for intestinal epithe-
lial cells,29,30 but the effects of GH on crypt cell prolif-
eration remain equivocal. Transgenic mice overex-
pressing GH show increased intestinal mass without
concomitant increases in crypt cell mitosis.16 One year of
GH replacement therapy in GH-deficient adults did not
increase colonic crypt cell proliferation.31 In this study,
we measured epithelial cell proliferation after DSS colitis
using 59-bromodeoxyuridine (BrdU) incorporation to es-
tablish whether MT1-bGH-TG mice show increased
crypt cell proliferation during recovery from DSS-in-
duced colitis.
Materials and Methods
Transgenic Mice
MT1-bGH-TG breeder pairs on a C57BL6/SJL genetic
background were provided by Drs. Richard Palmiter, Ralph
Brinster, and Richard Behringer.32 Hemizygous MT1-
bGH-TG males were mated with WT C57BL6/SJL females
( Jackson Laboratories, Bar Harbor, ME) to provide MT1-
bGH-TG and WT littermates for the experiments. MT1-
bGH-TG mice are readily distinguished from WT by in-
creased body weight, which is evident by postnatal day 28.
Genotype was verified on selected mice by polymerase chain
reaction (PCR) on tail DNA using oligomers (sense, 59- TT-
GACACAAACATGCGCAGT-39; antisense, 59-GCACT-
TCATGACCCTCAGGTAC-39) to the bovine GH gene,32
which revealed that genotyping by body weight was 100%
reliable.
Experimental Design
DSS (mol wt, 34,000–45,000) was purchased from
TDB Consultancy (Uppsala, Sweden). In pilot experiments,
adult (55–75-day-old) sex-matched MT1-bGH-TG and WT
littermates were given 4% or 3% (wt/vol) DSS in drinking
water for 5 days and then switched to water and monitored for
10 additional days. With the 4% dose of DSS, mortality
during the recovery phase was unacceptably high (see Results);
thus 3% DSS for 5 days was chosen as an optimal dose for
detailed analyses. At least 6 age- and sex-matched MT1-
bGH-TG and WT mice were studied at the end of 5 days of
3% DSS treatment (DSS) and at 3, 7, and 10 days after DSS
(DSS13, DSS17, and DSS110). Six control MT1-bGH-TG
and WT littermate pairs were allowed free access to drinking
water. Mice were housed individually in standard cages and
were allowed to drink and feed ad libitum. Animals were
weighed daily and stools were examined daily for blood
(Hemoccult; SmithKline Diagnostics, San Jose, CA). All ani-
mal experiments were approved by the Institutional Animal
Care and Use Committee of the University of North Carolina
at Chapel Hill. Study protocols were in compliance with the
Guide for the Care and Use of Laboratory Animals published by
the National Institutes of Health.
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Sample Collection
Mice were anesthetized by an intramuscular injection
of ketamine (900 mg/g body wt; Parke Davis, Morris Plains,
NJ) and xylazine (20 mg/g body wt; Barber Veterinary Supply,
Richmond, VA). Blood was collected by cardiac puncture, and
plasma was separated by centrifugation. Plasma IGF-I concen-
trations were measured by radioimmunoassay after extraction
on Sep-Pak C18 columns (Millipore, Bedford, MA) to remove
IGF binding proteins, as described previously.33 The entire
colon was dissected and contents flushed with ice-cold 0.9%
saline. The distal third of the colon was dissected and split into
three 0.5-cm segments (D1, D2, and D3). D1 and D2 were
fixed in 4% paraformaldehyde and Bouins fixative, respec-
tively, and then embedded in paraffin to provide sections for
histologic evaluation.24 The 2 different fixatives were used
merely to facilitate future immunohistochemical studies. D3
was oriented in O.C.T. Compound (Tissue Tek, Torrance, CA)
and frozen on dry ice and isopentane to provide frozen sections
for in situ hybridization histochemistry and additional sections
for histology. The remaining colon was homogenized imme-
diately in 4 mol/L guanidine thiocyanate, centrifuged to re-
move cell debris, then stored at 280°C for extraction of total
RNA.24 Mice were killed by exsanguination.
Histologic Scoring of Inflammation and
Crypt Damage
The distal colon was evaluated because this is the most
severely affected colonic segment in DSS-induced colitis.21,22
Sections from segments D1 and D3 were routinely scored.
Sections from segment D2 were scored in a small subset of
animals when the D1 or D3 sample showed poor morphology
or to verify scores obtained on other sections. Previous pilot
studies have established that evaluation of 2 or 3 segments of
distal colon provides a reliable histologic score that reflects
disease of the entire colon (P. Lund, unpublished observations,
June 2000). Inflammation and crypt damage were assessed on
H&E-stained, coded sections using a modification of a vali-
dated scoring scheme described by Cooper22 and Dieleman23 as
presented in Table 1. Total colitis score is the sum of the 3
subscores (inflammation severity, inflammation extent, and
crypt damage). Crypt hyperplasia has been noted during
recovery from acute DSS-induced colitis and crypt dysplasia
has been shown during chronic DSS-induced colitis.21 The
possibility that GH may increase susceptibility to dysplasia
is one potential concern in treating IBD patients with
GH.10 We therefore scored the frequency of obvious crypt
hyperplasia in MT1-bGH-TG or WT relative to controls
and also noted the frequency of atypical epithelial healing,
typified by bifurcated crypts, elevated lesions, and histo-
logic disarrangement of epithelium.21,22 Histologic evalua-
tion and scoring was performed using a Nikon Microphot-
FXA microscope (Nikon, Garden City, NY) equipped with
an Optronics DEI 750-3-chip (Optronics, Goleta, CA) CCD
camera for digital imaging.
RNA Extraction and Northern Blot
Hybridization Assays
Extraction of total RNA and Northern blot hybrid-
ization assays of IGF-I, IL-1b, and mouse ITF messenger
RNAs (mRNAs) were performed as previously described.24
32P-UTP–labeled mouse IL-1b,24 rat IGF-I,24 or mouse ITF
antisense RNAs were used as probes. The mouse ITF probe
was kindly provided by Dr. Daniel Podolsky (Massachusetts
General Hospital, Boston, MA). For TGF-b1 Northern
blots, a 327– base pair complementary DNA (cDNA) frag-
ment generated by PCR using primers (antisense, 59-GAG-
TGGTTATGATTTGATGT-39; sense, 59-GGTTCGTGAAT-
CCATTTCCA-3934) was labeled with 32P-dCTP. Blots were
reprobed with a mouse PL7 antisense RNA probe encoding a
constitutively expressed ribosomal protein24 or with an anti-
sense probe for the 28s ribosomal RNA (Ambion, Austin, TX),
depending on whether the size of the control RNA could be
readily distinguished from that of the test mRNA. Phospho-
imager analyses quantified the hybridization signals. Abun-
dance of IGF-I, IL-1b, ITF, and TGF-b1 mRNAs was nor-
malized to the abundance of PL7 mRNA or 28s rRNA to
control for minor differences in RNA loading. To normalize
across multiple blots, values for IL-1b, IGF-I, ITF, and
TGF-b1 mRNA abundance in each sample were expressed as
a ratio of the mean value observed in WT water controls
analyzed on the same blot.
In Situ Hybridization Histochemistry
IL-1b and IGF-I mRNAs were localized on frozen,
10-mm cryostat sections of colon that were postfixed in 4%
paraformaldehyde. In situ hybridization was performed us-
ing 35S-UTP–labeled antisense RNA probes as previously
described.24,35 Sections were observed and photographed
under light- and dark-field illumination using the Nikon
Table 1. Histologic Colitis Scoring Method
Feature scored Score Description
Inflammation severity 0 None
1 Mild
2 Moderate
3 Severe
Inflammation extent 0 None
1 Mucosa
2 Mucosa and submucosa
3 Transmural
Crypt damage 0 None
1 Basal 1⁄3 damaged
2 Basal 2⁄3 damaged
3 Crypts lost; surface epithelium
present
4 Crypts and surface epithelium
lost
Percent involvement 0 0%
1 1%–25%
2 26%–50%
3 51%–75%
4 75%–100%
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Microphot-FXA microscope and digital imaging system.
Sense RNA probes were used as specificity controls and gave
uniformly negative signals (data not shown).
BrdU Labeling of Proliferating Cells
To assess colonic crypt cell proliferation, 2–3 pairs of
MT1-bGH-TG and WT mice were treated with 3% DSS for 5
days and injected with 6.4 mg BrdU (Sigma, St. Louis, MO)
90 minutes before being killed at DSS13, DSS15, or DSS17.
Three pairs of water-treated control mice were also injected
with BrdU. The colon was opened longitudinally and carefully
rolled distal-to-proximal around a pipet tip, placed in an
embedding cassette to maintain orientation, and then embed-
ded in paraffin and sectioned. Immunohistochemistry was
performed using an horseradish peroxidase–conjugated sheep
anti-BrdU polyclonal antibody (Zymed, San Francisco, CA).
Labeling index, the number of BrdU-positive cells per crypt,
was assessed by a blinded observer. Only well-oriented, longi-
tudinally sectioned crypts were counted. Twelve to 24 crypts
were scored in each sample except in a small number of
sections, in which the extent of ulceration was such that this
was not possible.
Reverse-Transcription PCR Analyses of
TGF-a, Epidermal Growth Factor, and
TGF-b1–3
cDNAs were generated from pooled RNA samples
from mice of each genotype and treatment group using AMV
Reverse Transcriptase (Promega, Madison, WI). Semiquanti-
tative polymerase chain reaction was performed on each cDNA
for mouse TGF-a, epidermal growth factor (EGF), TGF-b1–3,
and glyceraldehyde-3-phosphate dehydrogenase using primers
based on published sequences. Primers were as follows:
TGF-a, antisense, 59-CCA CTG TCT ACA GTG GCA G-39,
sense, 59-CCT GTT AGC TGT GTG CCA GG-39; EGF,
antisense, 59-CCA TCG TAG GTC TCG AGT C-39, sense,
59-GCA ACT CCA CTC AGG CTG A-39; TGF-b1–3, anti-
sense, 59-GAG TGG TTA TGA TTT GAT GT-39, sense,
59-GGT TCG TGA ATC CAT TTC CA-3934; glyceraldehyde-
3-phosphate dehydrogenase, antisense, 59-GCC ATG AGG
TCC ACC ACC CTG TTG-39, sense primer, 59-CTA CTG
GCG CTG CCA AGG CTG T-39. The TGF-b primers cor-
respond to highly conserved regions in TGF-b1–3, and there-
fore measures amplify all 3 TGF-b isoforms.
Statistical Analysis
Values are expressed as mean 6 SE. Histologic scores
and values for IL-1b or IGF-I mRNA abundance were ana-
lyzed by 1-way analysis of variance followed by pairwise com-
parisons using Tukey’s test. Regression analyses were per-
formed to test for correlations between histologic measures of
disease and IL-1b or IGF-I mRNA abundance. A P value
,0.05 was considered statistically significant.
Results
GH Excess Enhances Survival During
DSS-Induced Colitis and Recovery
All MT1-bGH-TG and WT mice survived 5 days
of treatment with 4% DSS, but there was 25% mortality
of MT1-bGH-TG mice and 50% mortality of WT mice
during the 10 days after cessation of 4% DSS. Therefore,
this dose of DSS was not used further. With a 3% dose
of DSS, 100% of MT1-bGH-TG and WT mice survived
the 5-day treatment with DSS. During recovery, 100%
of MT1-bGH-TG (30 animals) survived the entire re-
covery phase, whereas 6 of 30 WT did not survive until
the designated study time. MT1-bGH-TG mice con-
sumed more DSS than their WT littermates during the
5 days of treatment (44.75 6 2.10 vs. 35.68 6 1.60 mL;
P , 0.05), so enhanced survival in MT1-bGH-TG mice
occurred despite consumption of more DSS than WT
mice. Euthanasia was performed when necessary because
of overt signs of serious disease (immobility and/or precip-
itous weight loss) in accordance with National Institutes of
Health and institutional Institutional Animal Care and Use
Committee guidelines regarding humane treatment of an-
imals. In both the 4% and 3% DSS treatment protocols,
death or need for euthanasia occurred between day 3 and 6
after DSS treatment.
GH Excess Improves Overt Signs of Disease
During Recovery Phase
Percent loss of body weight and percent of ani-
mals that were Hemoccult positive were used as gross
clinical indices of disease activity (Figure 1A and B).
Neither MT1-bGH-TG nor WT mice showed major loss
of body weight during DSS treatment. During the re-
covery phase, the MT1-bGH-TG and WT mice that
survived until the designated study time showed signif-
icant weight loss between day 2 and 5 after cessation of
DSS (Figure 1A ); mice began to gain weight by 5–6 days
after DSS treatment and had returned to their initial
weight by recovery day 7. In the animals that survived
until the designated study time, neither the magnitude
nor the time course of body weight loss differed signif-
icantly between MT1-bGH-TG and WT (Figure 1A ).
The WT mice that died or were killed during the
recovery phase showed significantly greater weight loss
consistent with more severe disease (Figure 1A ). During
DSS treatment, all but 1 MT1-bGH-TG and 1 WT
mouse became Hemoccult positive between day 3 and 5
of treatment and there was no evidence for a difference in
the time of disease onset between MT1-bGH-TG and
WT, even though MT1-bGH-TG mice consumed a
larger total amount of DSS. During the recovery phase,
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the percentage of Hemoccult-positive MT1-bGH-TG
mice declined much more rapidly than WT. Those WT
that died or were killed before the designated study time
remained Hemoccult positive until death.
GH Excess Reduces Inflammation and
Mucosal Damage During Recovery From
DSS-Induced Colitis
Detailed analyses of histology and mRNA abun-
dance and localization were performed only on those
MT1-bGH-TG and WT mice treated with 3% DSS that
survived until the intended study time. By excluding
from these analyses the most severely affected WT that
died or were killed during recovery phase, the effects of
GH on histologic and biochemical measures of disease
were probably underestimated. Mean histologic scores
for severity of inflammation, extent of inflammation,
crypt damage, and total colitis are shown in Table 2.
These scores did not differ significantly between MT1-
bGH-TG and WT littermates at the end of DSS treat-
ment or at DSS13. In both MT1-bGH-TG and WT
mice, each parameter of the colitis score was higher at
DSS13 than at the end of DSS treatment, indicating
that disease worsens in the period immediately after DSS
treatment. In WT mice, inflammation, crypt damage,
and total colitis scores showed no decline between 3 and
10 days after DSS administration. These scores were
decreased in MT1-bGH-TG mice at DSS17 and
DSS110, and at these time points, each score was sig-
nificantly lower in MT1-bGH-TG than in WT mice.
Figure 2 shows H&E-stained sections of the distal colon
from representative MT1-bGH-TG and WT mice at
different times after DSS to illustrate the similar inflam-
mation/crypt damage at the end of DSS treatment and
DSS13 and the reduced inflammation and crypt damage
in MT1-bGH-TG mice at DSS17 and DSS110. Obvi-
ous crypt hyperplasia was observed in a subset of MT1-
bGH-TG (44%) and WT (51%) mice during recovery
from DSS-induced colitis (Figure 3). Atypical epithelial
repair was observed in 32% of the WT analyzed during
Figure 1. (A) Percentage body weight change during DSS treatment
and recovery in MT1-bGH-TG (F), WT that survived until the designated
study time (E), and WT that did not survive until the intended study
time (h). Values are mean 6 SE of percentage body weight change in
each animal relative to weight at the start of DSS treatment. Percent-
age body weight change in water-treated MT1-bGH-TG (Œ) and WT
control (‚) are shown for reference at DSS treatment day 5, DSS17,
and DSS110. n $ 6 animals at each time point except for WT that
died or were killed. (B) Percentage of MT1-bGH-TG (F), WT (E), or WT
that did not survive recovery (h) that were Hemoccult positive on each
day during DSS treatment and recovery. (A) P , 0.05, DSS-treated WT
mice vs. intial body weight. (B) P , 0.05, DSS-treated MT1-bGH-TG
mice vs. initial body weight.
Table 2. Histologic Scores of Severity or Extent of Inflammation, Crypt Damage, and Total Colitis
Score Type DSS DSS 1 3 DSS 1 7 DSS 1 10
Inflammation severity TG 4.6 6 0.8 6.2 6 1.0 3.7 6 0.5a 4.7 6 0.3a
WT 4.1 6 0.9 7.8 6 1.8 7.5 6 1.3 7.9 6 1.3
Inflammation extent TG 3.9 6 0.4 6.6 6 0.7 3.4 6 0.6a 4.9 6 0.5a
WT 3.1 6 0.5 6.3 6 1.3 5.9 6 0.9 7.2 6 1.3
Crypt damage TG 2.8 6 0.7 4.5 6 1.2 2.2 6 0.5a 2.3 6 0.4a
WT 2.7 6 0.7 7.4 6 2.1 6.3 6 1.8 6.5 6 1.5
Total colitis TG 11.2 6 1.7 17.2 6 2.8 9.3 6 1.4a 11.9 6 1.0a
WT 10.0 6 2.1 21.5 6 5.2 19.6 6 4.0 21.6 6 3.8
aP , 0.05 MT1-bGH-TG vs. WT mice in the same treatment group. n 5 6 or 7 animals in each treatment group. Scores reflect evaluation of 2–3
segments of distal colon for each animal.
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the recovery phase but in no MT1-bGH-TG mice. Fig-
ure 3 shows examples of the atypical epithelial repair
observed in WT.
Expression of Colonic IL-1b mRNA Is
Increased in Both MT1-bGH-TG and WT
IL-1b mRNA expression was assayed as a bio-
chemical marker of inflammation. Figure 4A and B
shows representative Northern blots of IL-1b mRNA
and the mean IL-1b mRNA abundance in control and
DSS-treated MT1-bGH-TG and WT mice. DSS treat-
ment significantly elevated IL-1b mRNA in both MT1-
bGH-TG and WT mice, but there was considerable
variability in the absolute levels of IL-1b mRNA among
Figure 2. Representative photomicrographs of H&E-stained sections
of distal colon from (A, C, E, G, and I ) MT1-bGH-TG and (B, D, F, H, and
J ) WT mice. (A and B) Control mice; (C and D) end of DSS treatment;
(E and F ) DSS13; (G and H ) DSS17; (I and J ) DSS110. Bar 5 100
mm in all sections.
Figure 3. H&E-stained sections of colon during recovery phase show
crypt hyperplasia in (A) MT1-bGH-TG and (B) WT mice and (C and D)
atypical mucosal repair observed only in WT mice. Bar 5 500 mm in
all sections.
Figure 4. (A) Representative Northern blots show IL-1b and control
PL7 mRNA expression in colon of MT1-bGH-TG and WT mice. Water
controls and time points after DSS treatment are indicated. (B) Mean
IL-1b abundance in MT1-bGH-TG (F) and WT (E) mice. Values are
mean 6 SE of fold difference relative to the mean value in WT water
controls analyzed on the same blots. n $ 6 per condition or time
point. a P , 0.05 DSS-treated WT vs. WT control; b P , 0.05 DSS-
treated MT1-bGH-TG vs. MT1-bGH-TG control.
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animals and in the time course of IL-1b mRNA induc-
tion (Figure 4A ). Mean IL-1b mRNA abundance did not
differ significantly between MT1-bGH-TG and WT at
the end of DSS treatment or at any time point after DSS
treatment. Regression analyses revealed that the abun-
dance of IL-1b mRNA in individual DSS-treated MT1-
bGH-TG showed no significant correlation with any
colitis score (severity of inflammation, r 5 0.27, P 5
0.23; extent of inflammation, r 5 0.39, P 5 0.07; crypt
damage, r 5 0.03, P 5 0.89; and total colitis, r 5 0.24,
P 5 0.29). In DSS-treated WT mice, there were highly
significant correlations between IL-1b mRNA abun-
dance and severity of inflammation (r 5 0.64, P ,
0.001), extent of inflammation (r 5 0.67, P , 0.001),
crypt damage (r 5 0.66, P , 0.001), and total colitis
(r 5 0.67, P , 0.001). In situ hybridization revealed
similar sites of colonic IL-1b mRNA expression in
MT1-bGH-TG and WT mice. Data are shown for WT
in Figure 5. At the end of DSS treatment, IL-1b was
observed primarily in scattered cells within the lamina
propria. During the recovery phase, IL-1b was more
strongly and more widely expressed in the lamina
propria and in addition was observed in the muscularis
propria.
Plasma Levels of IGF-I and Colonic
Expression of IGF-I During DSS Colitis
and Recovery
Because IGF-I is a major mediator of GH ac-
tion, plasma IGF-I and local IGF-I expression were
measured to assess whether differences in IGF-I were
associated with effects of GH. Plasma levels of IGF-I
were significantly elevated in MT1-bGH-TG water
controls relative to control WT mice and were signif-
icantly greater in DSS-treated MT1-bGH-TG than in
WT mice at the end of DSS treatment and at DSS17
and DSS110 (Table 3). The latter time points corre-
spond to times when improved mucosal repair was
observed in MT1-bGH-TG mice. In WT mice, DSS
treatment did not significantly alter plasma IGF-I
levels relative to water controls. In MT1-bGH-TG
mice, plasma IGF-I levels were significantly lower
than in water controls at DSS13, DSS17, and
DSS110. Values in MT1-bGH-TG were lowest at
DSS13 when plasma IGF-I did not differ significantly
from WT. Colonic levels of IGF-I mRNA expression
were modestly increased in both MT1-bGH-TG and
WT mice at the end of DSS treatment relative to water
controls (Figure 6). IGF-I mRNA tended to remain
slightly elevated throughout the recovery phase, al-
though this did not achieve statistical significance
because of variability among animals. There was no
Figure 5. Dark-field (DF) and bright-field (BF) photomicrographs of
sections of distal colon from control or DSS-treated WT mice hybrid-
ized with an IL-1b antisense RNA probe. (A and B) Control; (C and D)
end of DSS; (E and F ) DSS13; (G and H) DSS17. Bar 5 500 mm.
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significant difference in mean IGF-I abundance in
colon of water or DSS-treated MT1-bGH-TG relative
to WT mice (Figure 6). IGF-I mRNA was localized in
colon at selected time points. Hybridization signals
for IGF-I tended to be low, and data are shown in
Figure 7 for those WT that exhibited convincing
hybridization signals. Localization patterns were sim-
ilar in MT1-bGH-TG mice (data not shown). IGF-I
mRNA was expressed in the lamina propria and mus-
cularis propria. Immune cell aggregates that were
observed in the mucosa during DSS-induced colitis
were negative for IGF-I mRNA (Figure 7G and H).
Hybridization signals revealed by in situ hybridiza-
tion tended to be higher for IGF-I mRNA during the
recovery phase even though Northern blot hybridiza-
tion data did not reveal significant increases in IGF-I
mRNA. This may reflect proportionate increases in
IGF-I mRNA and increases in the relative mass of
cells expressing other, more abundant mRNAs.
Improved Mucosal Repair in MT1-bGH-TG
Is Associated With Increased Crypt Cell
Proliferation
Because improved mucosal healing was evident in
MT1-bGH-TG mice by DSS17 but not at DSS13, fol-
low-up studies were performed in which BrdU was admin-
istered to a separate group of DSS-treated MT1-bGH-TG
and WT mice at DSS13, DSS15, and DSS17 to assess
whether increased crypt cell proliferation could account for
the effects of GH. DSS15 was included in this follow-up
study because we reasoned that elevated crypt cell prolifer-
ation may precede the first time point when improved
mucosal repair was evident in MT1-bGH-TG mice. Water
controls injected with BrdU were analyzed in parallel. As
shown in Table 4, the number of BrdU-positive cells per
crypt did not differ significantly in control MT1-bGH-TG
and WT mice. However, both MT1-bGH-TG and WT
showed increases in crypt cell proliferation during recovery
from DSS colitis, consistent with crypt regeneration as a
component of mucosal repair. Increased crypt cell prolifer-
ation was observed earlier in MT1-bGH-TG mice; numbers
of BrdU-positive cells per crypt were higher in MT1-
bGH-TG than in WT mice at DSS13 and DSS15. These
time points precede the improved mucosal repair in MT1-
bGH-TG at DSS17. In WT mice, significant increases in
numbers of BrdU-positive cells relative to WT water con-
trols were not observed until DSS17, indicating slower
crypt regeneration in WT than in MT1-bGH-TG.
Improved Mucosal Repair in MT1-bGH-TG
Reflects Increased Expression of ITF but
not TGF-b1–3, EGF, or TGF-a
Expression of ITF and TGF-b1, molecules impli-
cated in mediating mucosal repair, was assessed by
Table 3. Plasma IGF-I Concentrations (ng/mL)
H20 DSS DSS 1 3 DSS 1 7 DSS 1 10
TG 1509 6 92a 1700 6 133a 742 6 131b 1130 6 54a,b 1148 6 40a,b
WT 571 6 46 690 6 65 676 6 242 490 6 62 502 6 43
NOTE. Values are mean 6 SE for 6–10 animals per time point.
aP , 0.05 in MT1-bGH-TG vs. WT mice in the same treatment group.
bP , 0.05 in DSS-treated MT1-bGH-TG mice vs. water-treated MT1-bGH-TG controls.
Figure 6. (A) Representative Northern blots showing IGF-I and control
(PL7) mRNA expression in the colons of MT1-bGH-TG and WT mice.
Water controls and treatments are indicated. (B) Mean IGF-I mRNA
abundance in DSS-treated MT1-bGH-TG (F) and WT (E) mice. Values
are the mean 6 SE of the fold difference relative to the mean value of
WT water controls analyzed on the same blot. n $ 6 for each group.
a P , 0.05 DSS WT vs. WT control; b P , 0.05 DSS-treated MT1-
bGH-TG vs. MT1-bGH-TG controls.
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Northern blot in MT1-bGH-TG and WT mice. These
analyses were performed on 2 separate samples of pooled
RNA from 3 animals per genotype and treatment group
because of limited availability of RNA. Northern hy-
bridization of ITF mRNA revealed a modest increase in
steady-state mRNA abundance in control MT1-
bGH-TG relative to control WT mice (Figure 8). ITF
mRNA expression was also increased in MT1-bGH-TG
relative to WT at DSS13 and DSS17 (Figure 8). No
major differences in TGF-b1 mRNA abundance were
detected between MT1-bGH-TG and WT mice at any
time point (data not shown). EGF, TGF-a, and TGF-
b2–3 mRNAs were assessed by reverse-transcription
polymerase chain reaction. These analyses revealed low
expression of EGF, TGF-a, TGF-b2, and TGF-b3
mRNA, which showed no major induction at any time
after DSS and no evidence for significant differences
between MT1-bGH-TG and WT mice (data not shown).
Discussion
This study shows that chronic elevation of plasma
GH did not have a significant protective effect on the
onset or severity of acute colitis induced by DSS or
associated mucosal damage. GH excess did, however,
improve survival during recovery from colitis, promote
remission of inflammation, and enhance mucosal repair.
The more precipitous weight loss in the WT mice that
did not survive the recovery period compared with MT1-
bGH-TG supports the concept that anabolic effects of
GH to maintain body weight contributed to the en-
hanced survival of MT1-bGH-TG. Histologic evidence
of enhanced remission of inflammation and mucosal
damage as well as improved disease remission were ob-
served in MT1-bGH-TG, which showed a similar per-
centage loss in body weight as WT that survived recov-
ery phase. These data indicate that GH excess improves
recovery from colitis by specific effects on the colon.
Any proposed mechanism for the protective effects of
GH must take into account the fact that DSS treatment
Figure 7. Dark-field (DF) and corresponding bright-field (BF) photomi-
crographs of the distal colon of WT mice hybridized with IGF-I anti-
sense RNA probe. (A and B) Control; (C and D) end of DSS; (E and F )
DSS17; (G and H ) DSS110. All sections are shown at the same
magnification. Bar 5 500 mm.
Table 4. BrdU Labeling Index in DSS-Treated MT1-bGH-TG
and WT Mice
H20 DSS 1 3 DSS 1 5 DSS 1 7
TG 3.6 6 0.2 8.4 6 0.9a,b 5.5 6 0.6b 4.9 6 0.3b
WT 2.9 6 0.2 4.2 6 0.9 4.7 6 0.8 6.8 6 0.4c
NOTE. Values are means 6 SEM for the number of BrdU-positive cells
per crypt counted. n 5 13–65 crypts in 2–3 animals per treatment
group. The variation in number of crypts counted reflects the fact that
WT had fewer intact crypts than MT1-bGH-TG.
aP , 0.05 for MT1-bGH-TG vs. WT in the same treatment group.
bP , 0.05 for DSS-treated MT1-bGH-TG vs. control MT1-bGH-TG mice.
cP , 0.05 for DSS-treated WT vs. control WT mice.
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induced similar inflammation and crypt damage in MT1-
bGH-TG and WT and that MT1-bGH-TG showed re-
duced inflammation and crypt damage only during re-
covery from DSS. At the end of DSS treatment and
during the recovery phase, there were similar increases in
colonic IL-1b mRNA in MT1-bGH-TG and WT mice,
indicating that GH excess does not significantly alter the
induction of this proinflammatory cytokine. IL-1b
mRNA abundance showed a strong correlation with
inflammation, crypt damage, and total colitis in WT but
not MT1-bGH-TG mice, raising the intriguing possi-
bility that GH may inhibit the bioactivity of IL-1b
induced during intestinal inflammation; this possibility
warrants future investigation.
Crypt regeneration is an important component of mu-
cosal healing after acute inflammation and mucosal dam-
age.23,36 BrdU labeling data indicate that both MT1-
bGH-TG and WT mice show increased crypt cell
proliferation during recovery from DSS-induced colitis.
The more rapid increase in crypt cell proliferation in
MT1-bGH-TG than in WT mice provides evidence that
GH may improve or accelerate mucosal repair by effects
on crypt cell proliferation. This effect of GH seemed to
be transient because maximum increases in crypt cell
proliferation occurred at 3 days after DSS treatment,
before evidence of mucosal repair, and then declined
toward levels in water controls.
The transient effect of GH on crypt cell proliferation
rate is relevant to potential risks and benefits of GH
therapy during active IBD. As patients with IBD have an
increased risk of colorectal cancer, it would in fact be
desirable that therapy with trophic factors accelerate
mucosal repair and crypt regeneration without prolonged
effects to increase crypt cell proliferation. Our data in-
dicate that this may be a characteristic of GH action. In
addition, our data provide no evidence that GH excess
causes atypical epithelial repair. Bifurcated crypts, ele-
vated lesions, and histologic disarrangement of the epi-
thelium were observed in a significant number of WT
mice but in no MT1-bGH-TG mice. Thus, at least after
acute mucosal damage associated with colitis, our find-
ings provide no evidence that even dramatic GH excess
causes aberrant epithelial repair. In this regard, it is
noteworthy that multiple cycles of DSS cause chronic
colitis associated with crypt dysplasia.21 It will therefore
be of interest to evaluate if GH excess alters the fre-
quency of crypt dysplasia or neoplasia during chronic
DSS-induced colitis. Reduced crypt cell apoptosis repre-
sents another potential mechanism by which GH could
promote musocal healing. At present, there is little or no
information about the role of apoptosis in mucosal heal-
ing after colitis. However, a recent study in rats given
abdominal radiation showed that GH reduced radiation-
induced apoptosis of ileal epithelial cells, although not to
the same extent as IGF-I.37 This is clearly a potentially
interesting avenue of future investigation that is relevant
to the possible risks and benefits of GH therapy in IBD.
A major consideration is whether effects of GH to
promote mucosal healing or accelerated crypt cell prolif-
eration reflect direct actions of GH or indirect actions
mediated by other growth factors or known mediators of
mucosal repair. We assessed circulating and locally ex-
pressed IGF-I because IGF-I is a major mediator of GH
action27 and crypt epithelial cells are known targets for
IGF-I action.27,29,30 Plasma IGF-I levels were elevated in
DSS-treated MT1-bGH-TG mice relative to WT at the
end of DSS treatment and at DSS17 and DSS110, times
when improved mucosal repair was evident. It is there-
fore possible that endocrine actions of IGF-I contribute
Figure 8. (A) Representative Northern blot showing ITF mRNA and
control 28S ribosomal RNA expression in pooled samples from MT1-
bGH-TG and WT mice. Water-treated controls and treatment times are
indicated. (B) Mean ITF mRNA abundance in DSS-treated MT1-bGH-TG
(F) and WT (E) mice. Values are the means 6 SEM of the fold
differences relative to the values for WT water controls. Where error
bars are not shown, they are smaller than the size of the symbol. n 5
2 pooled samples of total RNA from 3 animals per treatment group.
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to improved mucosal healing in MT1-bGH-TG mice. It
is noteworthy, however, that the elevated plasma IGF-I
in MT1-bGH-TG at the end of DSS treatment was not
associated with any reduction in mucosal inflammation
or damage, indicating that neither GH nor IGF-I can
protect against mucosal damage. Furthermore, there was
not a direct temporal correlation between plasma IGF-I
levels and effects of GH to accelerate crypt cell prolifer-
ation and mucosal repair. At DSS13, a time associated
with maximal crypt cell proliferation in MT1-bGH-TG,
plasma IGF-I levels were actually lower than in water
controls and were not significantly different than in WT.
This decline in plasma IGF-I in MT1-bGH-TG is in-
triguing because it suggests that the early phase of
recovery from DSS-induced colitis may be associated
with an uncoupling of the ability of excess GH to
increase circulating IGF-I. It is established that proin-
flammatory cytokines such as IL-1b can inhibit the
action of GH to induce synthesis of IGF-I in the liver,
the major source of circulating IGF-I.38,39 If plasma
IL-1b were elevated during DSS colitis, this could in-
hibit the GH-induced production of IGF-I in the liver.
The findings about plasma IGF-I in MT1-bGH-TG mice
therefore do not exclude an endocrine role of circulating
IGF-I as a contributor to the enhanced mucosal healing
in MT1-bGH-TG mice, but they do not indicate a strict
correlation between the effects of GH on mucosal healing
and plasma IGF-I.
Colonic expression of IGF-I was elevated in DSS-
treated MT1-bGH-TG and WT mice, consistent with
our previous observations in WT mice given DSS,24
other rodent models of intestinal inflammation,35,40 and
patients with CD.41 The similar levels of local IGF-I
expression in DSS-treated MT1-bGH-TG and WT mice
suggest that local IGF-I expression is not increased by
circulating GH during acute colitis or during recovery
and probably does not contribute to the improved mu-
cosal repair in MT1-bGH-TG mice. Our prior studies
showed modest increases in local IGF-I expression in the
small intestine of normal MT1-bGH-TG mice.16 Our
current data in water and DSS-treated MT1-bGH-TG
mice indicate that the colon is less responsive to actions
of GH in terms of induction of local IGF-I expression.
Colonic IGF-I was expressed primarily in the lamina
propria and muscularis propria during DSS colitis and
was not obviously expressed in immune cell aggregates.
These findings suggest that IGF-I is expressed in mes-
enchymal cells during DSS-induced colitis, as we have
observed in other animal models of inflammation.35,40
Locally expressed, mesenchymal cell-derived IGF-I may
contribute to wound healing responses during intestinal
inflammation,27 but it does not seem to mediate im-
proved mucosal healing in MT1-bGH-TG mice.
Because we observed no evidence that locally expressed
IGF-I correlates with improved mucosal healing, we
assessed whether expression of other molecules that me-
diate mucosal healing or regeneration was altered in
MT1-bGH-TG mice. Our studies indicate that expres-
sion of ITF is slightly higher in control MT1-bGH-TG
mice than in WT. This may reflect increased mass of the
colonic mucosa and increased numbers of goblet cells,
which are sources of ITF.13,42 The higher level of ITF
mRNA in MT1-bGH-TG mice at DSS13 represents a
time when MT1-bGH-TG show similar crypt damage as
WT and so is probably not simply a reflection of in-
creased number of goblet cells. This evidence indicates
that GH excess may induce ITF expression and that ITF
may contribute to the beneficial effects of GH on muco-
sal healing. Other known mediators of wound healing,
such as EGF, TGF-a, and TGF-b1–3, were not found to
be elevated in control or DSS-treated MT1-bGH-TG
versus WT mice, and thus are not likely mediators of the
effects of GH to promote healing after DSS treatment.
In conclusion, our findings in MT1-bGH-TG mice
indicate beneficial effects of GH to promote mucosal
repair and remission of inflammation after acute DSS-
induced colitis by effects that include accelerated but
transient increases in crypt cell proliferation and no
evidence for atypical mucosal repair. These data add to a
growing body of evidence suggesting beneficial effects of
rhGH in patients with CD10–12 and indicate that some
effects of GH may be mediated by elevated circulating
IGF-I and colonic ITF expression.
References
1. Fiocchi C. Inflammatory bowel disease: etiology and pathogene-
sis. Gastroenterology 1998;115:182–205.
2. Sartor RB. Current concepts of the etiology and pathogenesis of
ulcerative colitis and Crohn’s disease. Gastroenterol Clin North
Am 1995;24:475–507.
3. Dieleman LA, Heizer WD. Nutritional issues in inflammatory bowel
disease. Gastroenterol Clin North Am 1998;27:435–451.
4. Savage MO, Beattie RM, Camacho-Hubner C, Walker-Smith JA,
Sanderson IR. Growth in Crohn’s disease. Acta Paediatr 1999;
88:89–92.
5. Kirschner BS, Sutton MM. Somatomedin-C: levels in growth-im-
paired children and adolescents with chronic inflammatory bowel
disease. Gastroenterology 1986;91:830–836.
6. Becker JM. Surgical therapy for ulcerative colitis and Crohn’s
disease. Gastroenterol Clin North Am 1999;28:371–390.
7. Byrne TA, Persinger RL, Young LS, Ziegler TR, Wilmore DW. A new
treatment for patients with short-bowel syndrome. Growth hor-
mone, glutamine, and a modified diet. Ann Surg 1995;222:243–
254.
8. Sax HC. New treatment for patients with short-bowel syndrome:
growth hormone, glutamine and a modified diet. JPEN J Parenter
Enteral Nutr 1996;20:375–376.
9. Wilmore DW, Lacey JM, Soultanakis RP, Bosch RL, Byrne TA.
March 2001 GROWTH HORMONE IMPROVES RECOVERY FROM DSS COLITIS 935
Factors predicting a successful outcome after pharmacologic
bowel compensation. Ann Surg 1997;226:288–292.
10. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA. Low-dose
recombinant human growth hormone increases body weight and
lean body mass in patients with short bowel syndrome. Ann Surg
1997;225:88–96.
11. Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD,
Sebo TJ, Batts KP, Kelly DG. Effect of growth hormone, glu-
tamine, and diet on adaptation in short-bowel syndrome: a ran-
domized, controlled study. Gastroenterology 1997;113:1074–
1081.
12. Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA,
McKinley MJ. A preliminary study of growth hormone therapy for
Crohn’s disease. N Engl J Med 2000;342:1633–1637.
13. Mashimo H, Wu DC, Podolsky DK, Fishman MC. Impaired de-
fense of intestinal mucosa in mice lacking intestinal trefoil factor.
Science 1996;274:262–265.
14. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC,
Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming
growth factor b1 null mutation in mice causes excessive inflam-
matory response and early death. Proc Natl Acad Sci U S A
1993;90:770–774.
15. Taylor B, Murphy GM, Dowling RH. Pituitary hormones and the
small bowel: effect of hypophysectomy on intestinal adaptation
to small bowel resection in the rat. Eur J Clin Invest 1979;9:115–
127.
16. Ulshen MH, Dowling RH, Fuller CR, Zimmermann E, Lund PK.
Enhanced growth of small bowel in transgenic mice overexpress-
ing bovine growth hormone. Gastroenterology 1993;104;973–
980.
17. Waitzberg DL, Cukier C, Mucerino DR, Logulo AF, Torrinhas RS,
de Castro I. Small bowel adaptation with growth hormone and
glutamine after massive resection of rat’s small bowel. Nutr
Hosp 1999;14:81–90.
18. Shulman DI, Hu CS, Duckett G, Lavallee-Grey M. Effects of
short-term growth hormone therapy in rats undergoing 75%
small intestinal resection. J Pediatr Gastroenterol Nutr 1992;
14:3–19.
19. Iannoli P, Miller JH, Ryan CK, Gu LH, Ziegler TR, Sax HC. Human
growth hormone induces system B transport in short bowel syn-
drome. J Surg Res 1997;69:150–158.
20. Vanderhoof JA, Kollman KA, Griffin S, Adrian TE. Growth hormone
and glutamine do not stimulate intestinal adaptation following
massive small bowel resection in the rat. J Pediatr Gastroenterol
Nutr 1997;25:327–331.
21. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y,
Nakaya R. A novel method in the induction of reliable experimen-
tal acute and chronic ulcerative colitis in mice. Gastroenterology
1990;98:694–702.
22. Cooper HS, Murthy SNS, Shah RS, Sedergran DJ. Clinicopatho-
logic study of dextran sulfate sodium experimental murine colitis.
Lab Invest 1993;69:238–249.
23. Dieleman LA, Palmen MJHJ, Akol H, Bloemena E, Pena AS,
Meuwissen SGM, Van Rees EP. Chronic experimental colitis
induced by dextran sulphate sodium (DSS) is characterized by
Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385–
391.
24. Savendahl L, Underwood LE, Haldeman KM, Ulshen MH, Lund
PK. Fasting prevents experimental murine colitis produced by
dextran sulfate sodium and decreases interleukin-1-beta and
insulin-like growth factor I messenger ribonucleic acid. Endocri-
nology 1997;138:734–740.
25. Arai Y, Takanashi H, Kitagawa H, Okayasu I. Involvement of
interleukin-1 in the development of ulcerative colitis induced by
dextran sulfate sodium in mice. Cytokine 1998;10:890–896.
26. Elson CO, Cony Y, Brandwein S, Weaver CT, McCabe RP, Mahler
M, Sundberg JP, Leiter EH. Experimental models to study molec-
ular mechanisms underlying intestinal inflammation. Ann N Y
Acad Sci 1998;3859:85–95.
27. Lund PK. IGFs and the digestive tract. The insulin-like growth
factors system. In: Roberts CT, Rosenfeld R, eds. The IGF sys-
tem. Totowa, NJ: Humana, 1999:517–544.
28. Yang H, Ney DM, Peterson CA, Lo H-C, Carey HV, Adamo ML.
Stimulation of intestinal growth is associated with increased
insulin-like growth factor–binding protein 5 mRNA in the jejunal
mucosa of insulin-like growth factor–I treated parenterally fed
rats. Proc Soc Exp Biol Med 1997;216:438–445.
29. Ohneda K, Ulshen MH, Fuller CR, D’Ercole AJ, Lund PK. Enhanced
growth of small bowel in transgenic mice expressing human
insulin-like growth factor I. Gastroenterology 1997;112:
444–454.
30. Simmons JG, Hoyt EC, Westwick JK, Brenner DA, Pucilowska JB,
Lund PK. Insulin-like growth factor-I and epidermal growth factor
interact to regulate growth and gene expression in IEC-6 intesti-
nal epithelial cells. Mol Endocrinol 1995;9:1157–1165.
31. Beentjes JS, van Gorkom BA, Sluiter WJ, de Vries EG, Kleibeuker
JH, Dullaart RP. One year growth hormone replacement therapy
does not alter colonic epithelial cell proliferation in growth hor-
mone deficient adults. Clin Endocrinol 2000;52:457–462.
32. Mathews LS, Hammer RE, Brinster RL, Palmiter RL. Expression of
insulin-like growth factor I in transgenic mice with elevated levels
of growth hormone is correlated with growth. Endocrinology
1988;123:433–437.
33. Underwood LE. Clinical uses of IGF-I and IGF binding protein
assays. In: Roberts CT, Rosenfeld R, eds. The IGF system. To-
towa, NJ: Humana, 1999:617–632.
34. Frank S, Madlener M, Werner S. Transforming growth factors b1,
b2, and b3 and their receptors are differentially regulated during
normal and impaired wound healing. J Biol Chem 1996;271:
10188–10193.
35. Zimmermann EM, Sartor RB, McCall RD, Pardo M, Bender D,
Lund PK. Insulin-like growth factor-I and interleukin 1 beta mes-
senger RNA in a rat model of granulomatous enterocolitis and
hepatitis. Gastroenterology 1993;105:399–409.
36. Tessner TG, Cohn SM, Schloemann S, Stenson WF. Prostaglan-
dins prevent decreased epithelial cell proliferation associated
with dextran sodium sulfate injury in mice. Gastroenterology
1998;115:874–882.
37. Mylonas PG, Matsouka PT, Papandoniou EV, Vagianos C, Kal-
farentzos F, Alexandrides TK. Growth hormone and insulin-like
growth factor I protect intestinal cells from radiation induced
apoptosis. Mol Cell Endocrinol 2000;160:115–122.
38. Thissen JP, Verniers J. Inhibition by interleukin-1 beta and tumor
necrosis factor-alpha of the insulin-like growth factor I messenger
ribonucleic acid response to growth hormone in rat hepatocyte
primary culture. Endocrinology 1997;138:1078–1084.
39. Wolf M, Bohm S, Brand M, Kreymann G. Proinflammatory cyto-
kines interleukin 1 beta and tumor necrosis factor alpha inhibit
growth hormone stimulation of insulin-like growth factor I synthe-
sis and growth hormone receptor mRNA levels in cultured rat liver
cells. Eur J Endocrinol 1996;135:729–737.
40. Zhee JM, Mohapatra N, Lund PK, Eysselein VE, McRoberts JA.
Differential expression and localization of IGF-I and IGF binding
proteins in inflamed rat colon. J Recept Signal Transduct Res
1998;18:265–280.
41. Pucilowska JB, Mohapatra NK, McNaughton KK, Hoyt EC, Zim-
mermann EM, Sartor RB, Lund PK. IGF-I and procollagen1(I) are
co-expressed in a subset of mesenchymal cells in active Crohn’s
disease. Am J Physiol 2000;279:G1307–G1322.
42. Podolsky DK. Mucosol immunity and inflammation. V. Innate
mechanisms of mucosal defense and repair: the best offense is
a good defense. Am J Physiol 1999;277:G495–G499.
936 WILLIAMS ET AL. GASTROENTEROLOGY Vol. 120, No. 4
Received March 23, 2000. Accepted November 9, 2000.
Address requests for reprints to: Kristen L. Williams, B.S., Depart-
ment of Cell and Molecular Physiology, University of North Carolina at
Chapel Hill, Chapel Hill, North Carolina 27599-7545. e-mail:
klwms@med.unc.edu; fax: (919) 966-6927.
Supported by a predoctoral fellowship from the Howard Hughes
Medical Foundation (to K.L.W.), a grant from the Crohn’s and Colitis
Foundation of America, and National Institutes of Health grant
DK47709 (to P.K.L. and R.B.S.). The study was facilitated by the
molecular histopathology core of the Center for Gastrointestinal Biol-
ogy and Disease (NIH P30-DK-34987) and mouse pathology, tissue
culture, and DNA synthesis cores of the Lineberger Cancer Center (NIH
CA16086).
The authors thank Dr. John Woosley for assistance with pathology,
Eileen Hoyt for assistance with image analyses, Evonne Bruton for
assistance with radioimmunoassays, Kirk McNaughton for assistance
with histology, and Deborah Carver for secretarial assistance.
March 2001 GROWTH HORMONE IMPROVES RECOVERY FROM DSS COLITIS 937
